Lahdenne Pekka, Panelius Jaana, Saxen Harri, Heikkilä Tero, Sillanpää Heidi, Peltomaa Miikka, Arnez Maja, Huppertz Hans-Iko, Seppälä Ilkka J T
Hospital for Children and Adolescents, University of Helsinki, Stenbäckinkatu 11, 00290 Helsinki, Finland 2Department of Bacteriology and Immunology, Haartman Institute, Haartmaninkatu 3, 00014 Helsinki, Finland 3,7Department of Otolaryngology3 and Laboratory Diagnostics7, Helsinki University Central Hospital, 00290 Helsinki, Finland 4Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA 5Department of Infectious Diseases, University Medical Center Ljubljana, Slovenia 6Professor-Hess-Children's Hospital Bremen and Children's Hospital of the University of Würzburg, Germany.
J Med Microbiol. 2003 Jul;52(Pt 7):563-567. doi: 10.1099/jmm.0.05095-0.
The performances of recombinant borrelial BBK32 proteins as antigens in the serology of erythema migrans (EM) were evaluated in an ELISA. Serum samples were obtained from 75 patients from different geographic areas where three borrelial species, Borrelia burgdorferi sensu stricto, Borrelia afzelii or Borrelia garinii, cause Lyme borreliosis. Antibodies to variant BBK32 proteins were compared with anti-flagella or with anti-IR(6) peptide antibodies. In IgG ELISA at presentation of EM, 65/75 (87 %) patients had antibodies to one or more variants of BBK32, 29/75 (39 %) had antibodies to flagella and 29/75 (39 %) had antibodies to the VlsE IR(6) peptide antigen. The immunoreactivity against variant BBK32 proteins differed in patients from different geographic regions. The present results suggest that the BBK32 proteins used in combination or in parallel may improve the laboratory diagnosis of EM.
在酶联免疫吸附测定（ELISA）中评估了重组疏螺旋体BBK32蛋白作为游走性红斑（EM）血清学抗原的性能。从75名来自不同地理区域的患者中获取血清样本，在这些地区，三种疏螺旋体，即狭义伯氏疏螺旋体、阿氏疏螺旋体或伽氏疏螺旋体，可引起莱姆病。将针对变异型BBK32蛋白的抗体与抗鞭毛抗体或抗IR(6)肽抗体进行比较。在EM出现时进行的IgG ELISA检测中，65/75（87%）的患者对一种或多种BBK32变异体具有抗体，29/75（39%）的患者对鞭毛具有抗体，29/75（39%）的患者对VlsE IR(6)肽抗原有抗体。来自不同地理区域的患者对变异型BBK32蛋白的免疫反应性有所不同。目前的结果表明，联合或并行使用BBK32蛋白可能会改善EM的实验室诊断。
